Moxifloxacina Aurobindo (Moxifloxacin Hydrochloride)

Moxifloxacin, the active ingredient in Moxifloxacina Aurobindo, is a fluoroquinolone antibiotic presented as an oral tablet for oral use. It treats bacterial infections such as community‑acquired pneumonia, acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, complicated skin and skin‑structure infections, and (off‑label) uncomplicated urinary tract infections in adult patients.

GNH USA supplies Moxifloxacina Aurobindo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Moxifloxacina Aurobindo is a fluoroquinolone antibiotic used to treat bacterial infections in several organ systems.

Community‑acquired pneumonia: achieves clinical cure and bacterial eradication. Acute bacterial sinusitis: reduces symptoms and clears the infecting pathogen. Acute bacterial exacerbation of chronic bronchitis: improves lung function and shortens disease course. Complicated skin and skin‑structure infections: eliminates causative bacteria and promotes wound healing. Uncomplicated urinary tract infections (off‑label): provides microbiological clearance in selected adult cases.

Moxifloxacina Aurobindo may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea - Diarrhea - Headache - Dizziness - Abdominal pain - Rash

Serious or Rare Side Effects: - Tendon rupture or tendinitis - QT interval prolongation leading to arrhythmia - Clostridioides difficile‑associated colitis - Severe allergic reactions (anaphylaxis, Stevens‑Johnson syndrome) - Hepatic toxicity (elevated transaminases, hepatitis) - Peripheral neuropathy

Before prescribing Moxifloxacina Aurobindo, clinicians should consider several safety measures.

Assess renal and hepatic function: adjust therapy if impairment is present. Avoid use in patients with known hypersensitivity to fluoroquinolones. Monitor for tendon pain or swelling: discontinue if tendonitis or rupture occurs. Evaluate QT interval in patients with cardiac risk factors. Avoid concomitant use with other QT‑prolonging drugs. Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Moxifloxacina Aurobindo can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Antacids containing aluminum or magnesium: markedly reduce moxifloxacin absorption. - Warfarin: may increase INR and bleeding risk. - Corticosteroids: heightened risk of tendon rupture. - Other fluoroquinolones (e.g., ciprofloxacin): additive tendon toxicity. - Drugs that prolong QT interval (e.g., macrolides, certain antiarrhythmics): risk of serious cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - Theophylline: may raise plasma concentrations, leading to toxicity. - Cyclosporine: increased exposure may require dose adjustment. - Diabetes medications: potential alteration of glycemic control.